| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
Following treatment with dexamethasone (10 µM), the proliferation rate of SH-SY5Y and 1242-MG was considerably boosted by rasagine (0.25 nM; 96 hours) [2].
|
|---|---|
| ln Vivo |
Under a transgenic model of multiple system atrophy, rasagiline is neuroprotective. Treatment with 2.5 mg/kg rasagiline improved motor impairments, according to motor behavior testing [3].
|
| Cell Assay |
Cell proliferation assay[2]
Cell Types: Neuroblastoma SH-SY5Y and Glioblastoma 1242-MG Tested Concentrations: 0.25 nM Incubation Duration: 96 hrs (hours) Experimental Results: Increased cell proliferation rate of SH-SY5Y cells treated with dexamethasone About 60%. The cell proliferation rate of 1242-MG cells treated with dexamethasone increased by approximately 35%. |
| Animal Protocol |
Animal/Disease Models: (PLP)-α-synuclein transgenic mice over 6 months old [3]
Doses: low dose (0.8 mg/kg bw) and high dose (2.5 mg/kg bw) Route of Administration: every subcutaneous injection once every 24 hrs (hrs (hours)) for 1 time. The total time was 4 weeks (from day 1 to day 28 of the experiment). Experimental Results: Low-dose treatment demonstrated no protective effect in the striatum, with neuronal numbers similar to those in placebo-treated MSA mice. High doses were associated with approximately 15% rescue of DARPP-32-immunoreactive striatal neurons. Low-dose treatment had no effect on nigral neuronal loss, but high-dose treatment completely protected nigral neurons in numbers comparable to healthy controls. |
| References |
[1]. M B Youdim, et al. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001 Jan;132(2):500-6.
[2]. Shawna Tazik, et al. Comparative neuroprotective effects of Rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotox Res. 2009 Apr;15(3):284-90. [3]. Nadia Stefanova, et al. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol. 2008 Apr;210(2):421-7. |
| Molecular Formula |
C12H13N
|
|---|---|
| Molecular Weight |
171.2383
|
| CAS # |
136236-51-6
|
| Related CAS # |
Rasagiline mesylate;161735-79-1;Rasagiline-13C3 mesylate racemic;1216757-55-9
|
| SMILES |
N([H])(C([H])([H])C#C[H])[C@@]1([H])C2=C([H])C([H])=C([H])C([H])=C2C([H])([H])C1([H])[H]
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~583.98 mM)
H2O : ≥ 5.88 mg/mL (~34.34 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8398 mL | 29.1988 mL | 58.3976 mL | |
| 5 mM | 1.1680 mL | 5.8398 mL | 11.6795 mL | |
| 10 mM | 0.5840 mL | 2.9199 mL | 5.8398 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
